| Project/Area Number |
23592342
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SATO Noriyuki 札幌医科大学, 医学部, 教授 (50158937)
TORIGOE Toshihiko 札幌医科大学, 医学部, 准教授 (20301400)
MASUMORI Naoya 札幌医科大学, 医学部, 教授 (20295356)
塚本 泰司 札幌医科大学, 医学部, 名誉教授 (50112454)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 腫瘍学 / がんワクチン / 膀胱癌 / 再発予防 / 腫瘍抗原 |
|---|
| Research Abstract |
Peptides SVNC-S, containing an MHC class I-restricted epitope, and SVNC-L, containing MHC class I- and II-restricted epitopes, were derived from the amino acid sequence of survivin. Vaccination with SVNC-L induced a more powerful immune response than that with SVNC-S. The SVNC-L vaccination resulted in more significant suppression of the tumour growth than vaccination with SVNC-S. The SVNC-L vaccination also prevented BBN-induced bladder carcinogenesis.
|
